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INT ROD UCT ION
Type 2 cytokine responses are characterized by the devel-
opment of  T helper type 2 cells (Th2 cells), IL-4, -5, -9, and 
-13 expression, basophil and mast cell responses, and increased 
IgE production. Type 2 cytokines are necessary for the devel-
opment of protective immunity to helminth parasites and also 
promote the pathology associated with allergies and asthma 
(Allen and Maizels, 2011; Pulendran and Artis, 2012). Hel-
minth parasites infect an estimated 2 billion people and cause 
anemia, retarded growth, and exert enormous economic 
burdens on heavily infected areas (Allen and Maizels, 2011). 
Allergic diseases including food allergies have risen to epi-
demic proportions in developed areas of the world and result 
in significant morbidity and even death (Pulendran and Artis, 
2012). Current therapeutic strategies to treat helminth infec-
tions and allergic inflammation are limited by our incomplete 
understanding of the events that promote type 2 inflamma-
tion (Pulendran and Artis, 2012).
An emerging body of literature has identified that type 
2 inflammation can be promoted by specialized progenitor 
cells that enter peripheral tissues and undergo in situ hema-
topoiesis. These studies demonstrate that lineage negative, 
CD34+, c-Kit+ hematopoietic progenitors accumulate in pe-
ripheral tissues after stimulation with cytokine alarmins, ex-
posure to helminths, or the initiation of allergic inflammation 
(Saenz et al., 2010; Siracusa et al., 2013). The conserved pres-
ence of these progenitors in the context of type 2 responses 
allows them to be characterized as type 2 associated. It has 
been shown that type 2 progenitors promote inflammation 
via their enhanced ability to develop into mast cells com-
pared with phenotypically similar BM-resident progenitors 
(Siracusa et al., 2013). Collectively, these studies suggest that 
targeting progenitors to prevent mast cell differentiation may 
be sufficient to regulate type 2 inflammation.
Here, we show that type 2 progenitors express elevated 
levels of carbonic anhydrase (Car) enzymes. Car enzymes are 
a family of metabolic enzymes that regulate pH and CO2 
homeostasis and have been targeted to treat diseases including 
glaucoma and gastric ulcers (Supuran, 2008). Car enzymes 
have also been associated with type 2 cytokine responses 
(Kamsteeg et al., 2007; Wen et al., 2014). Our experiments 
demonstrate that pan-inhibition of Car enzymes with an 
FDA-approved inhibitor was sufficient to prevent inflamma-
tory mast cell responses in the context of helminth infection 
and models of allergic inflammation. In contrast, Car enzyme 
inhibition promoted immunity to Aspergillus fumigatus, sug-
gesting that Car enzymes can selectively affect specific im-
mune modules. Furthermore, selectively editing Car1 via 
CRI SPR/Cas9 was sufficient to reduce mast cell develop-
ment from stem cells but had no effect on macrophage com-
mitment. Finally, we demonstrate that Car enzyme inhibition 
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was also sufficient to prevent human mast cell development. 
Collectively, these studies identify a previously unappreci-
ated mechanism through which mammalian immune cells 
are instructed by inflammatory cues and provide insight 
into the therapeutic potential of targeting Car1 to treat mast 
cell–mediated inflammation.
RES ULTS AND DIS CUS SION
Mast cells express elevated levels of Car enzymes
We first compared the transcriptional profiles of naive BM-res-
ident progenitors to those of type 2 progenitors (Siracusa et 
al., 2013) to identify fundamental pathways associated with 
mast cell development. The top 200 genes expressed at higher 
levels in type 2 progenitors were run through pathway analysis 
(Dennis et al., 2003). Type 2 progenitors were enriched for 
genes associated with immune and defense responses, hemato-
poietic lineages, responses to wounding, and asthma (Fig. 1 A). 
Type 2 progenitors also expressed genes associated with ser-
ine hydrolases, known to be present in mast cells (Long and 
Cravatt, 2011), and carbon–oxygen lyase activity (Fig. 1 B). 
The carbon–oxygen lyase pathway was comprised of the genes 
encoding Car enzymes 1 and 2. To confirm these data, we sort 
purified Trichinella spiralis–induced progenitors from infected 
mice (Siracusa et al., 2013) and compared Car1 and 2 expres-
sion to that of naive BM progenitors. The genes encoding 
Car1 and 2 were expressed at significantly higher levels in 
T. spiralis–induced progenitors (Fig. 1 C). Collectively, these 
data demonstrate that Car1 and 2 are highly expressed in mast 
cell precursors. Next, we sort purified BM-derived basophils 
and mast cells, CD8 T cells, CD4 T cells, B cells, macro-
phages, and monocytes and evaluated their expression levels of 
Car1 and 2. Car1 and 2 were expressed at significantly higher 
levels in mature mast cells compared with other populations 
(Fig. 1 D). These data provoke the hypothesis that Car1 and 2 
may regulate mast cell development.
Car enzyme inhibitors prevent in 
vitro mast cell development
The Car enzyme inhibitor methazolamide (MZ) has been 
shown to inhibit Car1 and 2 (Supuran, 2008). Therefore, we 
used mast cell developmental assays (Saenz et al., 2010; Sir-
acusa et al., 2011, 2013) to determine whether Car enzyme 
inhibition affected mast cell development. Critically, cultures 
treated with MZ exhibited significantly reduced mast cell 
populations compared with controls (Fig. 1 E). In addition 
to mast cells, type 2 progenitors are also capable of develop-
ing into basophils (Siracusa et al., 2013). Therefore, we sought 
to determine whether Car enzyme inhibition altered baso-
phil development. Although treatment of cultures with MZ 
resulted in significantly increased percentages of basophils 
(Fig. 1 F), Car enzyme inhibition resulted in decreased baso-
phil numbers. Next, we sought to determine whether Car en-
zyme inhibition alters the development of other myeloid cell 
populations (Marim et al., 2010). Importantly, treatment with 
MZ had no effect on macrophage development (Fig. 1 G).
Inhibition of Car enzymes is sufficient to prevent 
infection-induced mastocytosis
Protective immunity to T. spiralis is dependent on type 2 
cytokine responses and is associated with the population ex-
pansion of mast cells and basophils (Urban et al., 2000; Gia-
comin et al., 2012). Therefore, T. spiralis–infected mice were 
treated with vehicle or MZ, and mast cells and basophils were 
monitored. T. spiralis infection resulted in increased percent-
ages and numbers of mast cells in the mesenteric LNs (mLNs; 
Fig. 2, A and B), increased serum levels of mast cell protease 
1 (Mcpt1; Fig. 2 C), increased expression of intestinal mcpt1 
(Fig.  2  D), and increased intestinal mast cells identified by 
histological analysis (Fig. 2 E). Critically, treatment of mice 
with MZ resulted in significantly reduced mast cell responses 
across these parameters (Fig. 2, A–E). In contrast to mast cells, 
treatment of T. spiralis–infected mice with MZ had no effect 
on infection-induced basophilia (Fig. 2, F and G). These ex-
periments suggest that the moderate effects of Car enzyme 
inhibition on in vitro basophil development (Fig. 1 F) may be 
a result of its actions on a limited pool of common progenitors 
shared between basophils and mast cells (Voehringer, 2013).
Mast cells have been shown to play critical roles in the 
development of protective immunity to T. spiralis (Urban et 
al., 2000; Voehringer, 2013). Therefore, we sought to deter-
mine whether the inhibition of T. spiralis–induced mast cell 
responses correlated with reduced inflammation and immu-
nity. As expected (Urban et al., 2000), T. spiralis–infected mice 
exhibited increased levels of IL-4, IL-5, and IL-13 produc-
tion from mLN cells (Fig. 3 A), increased intestinal expres-
sion of il4, il9, arg1, and retnla (Fig. 3 B), and elevated serum 
levels of IgE (Fig.  3 C). Critically, T. spiralis–infected mice 
treated with MZ exhibited significantly reduced type 2 
responses as measured by these parameters (Fig.  3, A–C). 
Moreover, significantly more worms were recovered from the 
intestines of mice treated with MZ (Fig.  3  D). These data 
demonstrate that Car enzyme–mediated inhibition of mast 
cell responses is associated with reduced inflammation and a 
loss of protective immunity.
The ability of MZ to regulate inflammation could be 
a result of its effects on mast cells, lymphocytes, or global 
immunosuppressive qualities. Therefore, we first used a model 
of atopic dermatitis–like disease in which type 2 cytokine 
responses and pathology are dependent on group 2 innate 
lymphoid cells (ILC2) and basophils (Kim et al., 2013, 2014a). 
Critically, mice treated with MC903 in the presence of MZ 
exhibited equivalent or significantly increased type 2 cyto-
kine production and similar atopic dermatitis–like pathology 
as controls (Fig. 3, E and F). These data demonstrate that Car 
enzyme inhibition does not result in reduced ILC2- and ba-
sophil-dependent type 2 cytokine responses.
Mast cells are reported to operate as initiators of 
T. spiralis–induced Th2 cell development (Knight et al., 2000; 
Urban et al., 2000) but are also supported by T cell activation 
(Voehringer, 2013). Therefore, we treated Rag1–deficient 
mice with IL-3–anti–IL-3 complexes (IL-3C) and moni-
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Figure 1. Mast cell development is associated with increased expression of Car enzymes. Transcriptional profiles of BM-resident or type 2 progen-
itors were compared. (A and B) Enriched pathways in type 2 progenitors were identified, and gene ontology (GO) terms were listed. (C) Progenitors were 
purified from the BM of naive mice or the spleens of T. spiralis (Ts)-infected mice, and gene expression was determined. (D) Cell populations were purified 
from naive mice or cell cultures, and gene expression (relative to basophils [Baso]) was determined. Mac, macrophage; MC, mast cell; Mono, monocyte. 
(E–G) BM-resident progenitors were isolated and cultured with IL-3 or L cell culture supernatant (L-sup) in the presence of vehicle (Veh) or MZ, and mast 
cells (E), basophils (F), and macrophages (G) were quantified. (C) Results are representative of three to five pooled biological replicates. (D) Results are rep-
resentative of four biological replicates. (E-G) Results are representative of at least three individual experiments. Numbers in cytometry plots represent the 
percentage of cells gated. Statistical analysis was performed using a Student’s t test. *, P < 0.05; ***, P < 0.001. Error bars represent SD.
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tored intestinal mast cell responses and peripheral basophilia 
(Finkelman et al., 1993; Ohmori et al., 2009). MZ treatment 
resulted in significantly reduced mast cell responses but had 
no effect on IL-3C–induced basophilia in Rag1-deficient 
animals (Fig. 3 G). These data demonstrate that Car enzyme 
inhibition is sufficient to selectively inhibit mast cell responses 
in lymphocyte-sufficient and -deficient environments.
Next, we sought to determine whether Car enzyme 
inhibition promotes immunosuppressive qualities. A. fumi-
gatus is an opportunistic pathogen that thrives in immu-
nosuppressed hosts (Espinosa et al., 2014). Infecting mice 
with fluorescent A. fumigatus reporter conidia (Espinosa 
et al., 2014) allows live and dead spores to be identified in 
vivo. Neutrophil responses and fungal clearance were in-
creased in MZ-treated mice (Fig.  3, H–J). Collectively, 
these data demonstrate that Car enzyme inhibition does not 
promote broad immunosuppressive effects but rather en-
hances antifungal immunity.
Inhibition of Car enzymes is sufficient to prevent food 
allergy–induced mast cell responses
Food allergies are a significant and growing public health con-
cern (Sicherer and Sampson, 2014). Mast cells are critically 
important to the development of intestinal inflammation after 
sensitization and challenge with food antigens (Wang et al., 
2010). Therefore, we used a model of food allergy–like disease 
that promotes intestinal mastocytosis (Noti et al., 2014) and 
treated mice with vehicle or MZ. Mice sensitized and chal-
lenged with chicken ovalbumin, a food allergen found in eggs 
(Dang et al., 2014), exhibited increased serum levels of Mcpt1 
(Fig. 4 A), elevated intestinal expression of mcpt1 (Fig. 4 B), 
increased intestinal mast cells identified by histological analysis 
(Fig. 4, C and D), and increased serum levels of IgE (Fig. 4 E). 
MZ-treated mice exhibited significantly decreased mast cell 
responses across all of these parameters (Fig. 4, A–D) but had 
significantly increased IgE levels (Fig. 4 E). Collectively, these 
experiments demonstrate that pharmacologic inhibition of 
Figure 2. Car enzymes regulate infection-induced mastocytosis. T. spiralis–infected (INF) mice were treated with Veh or MZ, and mast cells in the 
mLNs (A and B), serum levels of Mcpt1 (C), intestinal expression of mcpt1 (D), intestinal mast cells per high-power field (hpf) in histological sections (E), and 
splenic basophils (F and G) were evaluated. Results are representative of at least three individual experiments with at least two mice per naive group and at 
least three mice per T. spiralis–infected group. Numbers in cytometry plots represent the percentage of cells gated. Statistical analysis was performed using 
a Student’s t test. *, P < 0.05; **, P < 0.01. Error bars represent SD.
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Car enzymes is sufficient to significantly reduce food allergy–
induced mast cell responses. Furthermore, the increased levels 
of IgE observed in MZ-treated mice suggest this treatment is 
not inhibiting lymphocyte activation. The increases observed 
are likely a result of reductions in mast cell populations capa-
ble of binding soluble IgE.
Figure 3. Inhibition of Car enzymes is sufficient to inhibit mast cell–mediated inflammation. T. spiralis–infected mice (INF) were treated with Veh or 
MZ. (A–D) Isolated mLN cells were stimulated and levels of IL-4, IL-5, and IL-13 (A), intestinal expression of il4, il9, arg1, and retnla (B), serum IgE levels (C), 
and worm burdens (D) were evaluated. (E and F) Mice were treated with ethanol (EtOH) or MC903 and Veh or MZ. Skin-draining LN cells were stimulated, 
and levels of IL-4, IL-5, and IL-13 (E) and skin pathology (F) were evaluated. Error bars represent SD. Bars, 50 µm. (G) Rag1−/− mice were treated with PBS 
or IL-3C and Veh or MZ. Intestinal mast cells and splenic basophils were evaluated. hpf, high-power field. (H-J) A. fumigatus–infected mice were treated 
with Veh, MZ, or anti-Ly6G, and neutrophil responses and lung fungal burdens were determined. Results are representative of at least three independent 
experiments with at least two mice per naive group and at least three mice per experimental group. Statistical analysis was performed using a Student’s t 
test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Car1 positively regulates mast cell development
We show that inhibition of Car enzyme family members via a 
pan inhibitor is sufficient to prevent helminth- or allergen-in-
duced mastocytosis. However, whether specifically targeting 
Car1 or 2 is sufficient to regulate mast cell responses remains 
unknown. To address this, we lethally irradiated mice and re-
Figure 4. Car enzymes regulate human mast cell development. OVA challenged (chal) or sensitized and challenge (sen/chal) mice were treated with Veh 
or MZ. Serum Mcpt1 (A), intestinal expression of mcpt1 (B), intestinal mast cell populations in histological sections (C and D), and serum IgE levels (E) were 
evaluated. hpf, high-power field. Bars, 100 µm. (F) Mice were reconstituted with WT and Car2−/− BM (50/50), and the percent chimerism was determined. 
(G and H) Chimeric mice were infected with T. spiralis (Ts), and mLN mast cells were evaluated. (I) Mice reconstituted with 100% WT or 100% Car2−/− BM 
were infected with T. spiralis, and intestinal expression of Car1 was determined. (J and K) Mock-edited or Car1-edited stem cells were cultured under mast 
cell (J)– or macrophage (K)-promoting conditions. (L and M) Human CD34+ cells were cultured with mast cell–promoting cytokines in the presence of Veh 
or MZ. Representative analysis is from one donor. Error bars represent SD. (N) Pooled mast cell numbers from five individual donors. (A and B) Results are 
illustrated as the combined datasets of three independent experiments. (C–E) Results are representative of three independent experiments of at least two 
mice per challenged group and at least three mice per sensitized and challenged group. (F and H) Results are representative of two independent experiments 
of nine biological replicates total. (I) Results are representative of 2 independent experiments of 10 biological replicates total. (J and K) Results are represen-
tative of three independent experiments with at least three technical replicates per experiment. (L and M) Results illustrate three technical replicates from 
one human donor. (N) Data points represent individual human donors. n = 5. Numbers in cytometry plots represent the percentage of cells gated. Statistical 
analysis was performed using a Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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constituted them with BM cells from WT and Car2−/− mice 
at a 50:50 ratio. Both WT and Car2−/− cells were present at 
equal percentages (Fig. 4 F); however, when chimeric mice 
were infected with T. spiralis, ∼80% of T. spiralis–induced 
mast cells were derived from Car2−/− cells (Fig. 4, G and H). 
These data countered our working hypothesis that Car1 and 
2 promote mast cell development. It has been shown previ-
ously that deletion of one Car enzyme can result in the in-
creased expression of other family members (Pan et al., 2006). 
Interestingly, we found that chimeric mice reconstituted 
with 100% Car2−/− cells expressed higher levels of Car1 after 
T. spiralis infection than mice reconstituted with WT BM 
(Fig. 4 I). Collectively, these data provoke the hypothesis that 
Car1 operates as a positive regulator of mast cell development.
Because Car1-deficient mice are not readily available, we 
used CRI SPR/Cas9 technology to genetically edit Car1 in 
mouse embryonic stem cells (ESCs). Car1 was edited in ∼60% 
of ESCs electroporated with Car1-specific RNA guides and 
Cas9 protein (unpublished data). Furthermore, when Car1- 
edited stem cells were cultured, they exhibited a reduced 
capacity to develop into mast cells compared with controls 
(Fig. 4 J) but showed no defect in macrophage development 
(Fig. 4 K). Collectively, these experiments illustrate that CRI 
SPR/Cas9-mediated editing of Car1 results in a selective 
reduction in mast cell hematopoietic potential. However, 
whether Car1 regulates mast cell development via its effects 
on other Car family members requires further examination.
Car enzyme inhibition is sufficient to prevent 
human mast cell development
Patients suffering from allergic diseases such as food allergies 
present with increased mast cell responses, suggesting that 
targeting mast cell development may represent a viable ther-
apeutic strategy (Reimann and Lewin, 1988; Bischoff and 
Crowe, 2005; Ramsay et al., 2010; Voehringer, 2013). Here, 
we have identified that mouse Car1 operates as a positive 
regulator of mast cell development. However, whether Car 
enzymes can be targeted to prevent human mast cell de-
velopment remains unknown. Therefore, we isolated CD34+ 
progenitor cells from the blood of healthy human donors 
and used an established protocol to grow human mast cells 
(Saito et al., 2006). Human cultures treated with MZ exhib-
ited significantly reduced percentages and total numbers of 
mast cells (Fig. 4, L and M). The ability of MZ to prevent 
human mast cell development was found to be consistent 
across five individual donors (Fig. 4 N).
Recent studies have begun to introduce a model 
through which alterations in metabolic processes can instruct 
immune cell development and activation (Pearce and Pearce, 
2013). Variations in pH often accompany infectious and in-
flammatory insults and can have potent effects on immune 
cell function (Lardner, 2001). The experiments presented here 
suggest that, similar to germline-encoded receptors that rec-
ognize pathogen-derived molecules (Tang et al., 2012), Car 
enzymes may operate as sensory mechanisms that instruct 
immune cell hematopoiesis under inflammatory conditions. 
This hypothesis is supported by a recent study identifying 
Car4 as the signature gene expressed by pulmonary macro-
phages (Lavin et al., 2014). Here, our data suggest that Car1 
operates as a positive regulator of mast cell development and 
that targeting Car1 may prove to be effective in treating mast 
cell–mediated inflammation.
MAT ERI ALS AND MET HODS
Mice
C57BL(6) WT mice were purchased from The Jackson Labo-
ratory. Mice were maintained in specific pathogen–free facil-
ities at the Rutgers New Jersey Medical School. All protocols 
were approved by the Rutgers Institutional Animal Care and 
Use Committee. Car2-deficient mice on a C57BL(6) back-
ground were provided by M. Soleimani (University of Cin-
cinnati, Cincinnati, OH).
Flow cytometry and cell sorting
Cells were stained with monoclonal anti–mouse fluores-
cently conjugated antibodies: Sca-1 (D7), c-Kit (ACK2), 
CD3 (145-2C11), CD4 (GK1.5), CD8 (SK1), CD5 (53-73), 
CD19 (1D3), NK1.1 (PK136), CD11b (MI/70), CD11c 
(N418), CD16(32) (93), IgE (23G3), FcεRI (MAR-1), 
CD49b (DX5), CD115 (AFS98), F4/80 (BM8), and CD34 
(RAM34) from eBioscience; or monoclonal anti–human 
fluorescently conjugated antibodies: CD19 (HIB19), FcεRI 
(AER-37), CD34 (4H11), c-Kit (104D2), and TCRαβ 
(IP26) from eBioscience. Samples were acquired on an LSR 
II or LSR FOR TES SA X-20 flow cytometer (BD) and ana-
lyzed using FlowJo software (v10.0.5; Tree Star). Cell sorting 
was performed using a FAC SAria II flow cytometer (BD). 
BM-resident and splenic progenitors were sort purified as 
CD3−, CD19−, CD11b−, CD11c−, NK1.1−, Sca-1−, FcεRI−, 
CD34+, and c-Kit+ cells. Splenic progenitors were isolated 
on day 7 after T. spiralis infection.
Microarray and gene expression analysis
Genome-wide transcriptional profiles were downloaded 
from the NCBI Gene Expression Omnibus (GEO) under 
the accession no. GSE52485. The Affymetrix CEL files from 
BM progenitor datasets (GEO accession no.s GSM1267747, 
GSM1267748, and GSM1267749) and type 2 progenitor 
datasets (GEO accession nos. GSM1267744, GSM1267745, 
and GSM1267746) were loaded into Genomics Suite soft-
ware (version 6.6; Partek Inc.). The CEL files were RMA 
normalized, and a one-way ANO VA analysis was performed. 
A subset of the top 200 annotated genes, which were up-reg-
ulated in type 2 progenitors versus BM progenitors and that 
passed a p-value cut off of ≤0.05, was then merged with the 
RMA-normalized signal intensities and exported as a text 
file. The top 200 enriched genes in type 2 progenitors were 
analyzed for gene pathways with the Database for Annotation, 
Visualization and Integrated Discovery.
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Isolation and processing of immune cells for 
Car expression profiling
Indicated cell populations were isolated from four naive 
CCR2-GFP mice on a C57BL(6) background. B cells and 
T cells were sorted from spleens. B cells were sort purified 
as CD45+ CD11c− NK1.1− CCR2GFP− B220+. T cells 
were sort purified as CD45+ CD11c− NK1.1− CCR2-GFP− 
B220− Thy1.2+ and either CD4+ or CD8+. Macrophages and 
monocytes were isolated from collagenase-digested lungs. 
Macrophages were sort purified as CD45+ F480+ Siglec F+ 
CD11c+ MHC II+. Monocytes were sort purified as CD45+ 
CD11b+ CCR2GFP+ NK1.1− CD11c−. BM-derived mast 
cells were sort purified as CD3− CD19− CD49b− CD200R+ 
c-Kit+ and BM-derived basophils as CD3− CD19− c-Kit− 
CD200R+ CD49b+. BM-derived cells were sort purified on 
day 7 after culture. Purity for all cell populations was deter-
mined to be ≥98%. RNA was extracted using an RNA iso-
lation kit (RNeasy; QIA GEN) and amplified using an RNA 
amplification kit (MessageAmp II; Ambion). Relative mRNA 
levels were determined by real-time PCR. RNA was reverse 
transcribed using a High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystems). For each gene, Taq Man 
Fast Universal PCR Master Mix (2×) No Amp and TaqMan 
probes (Applied Biosystems) were used.
Mouse mast cell and basophil cultures
BM cells were isolated from the femur of WT mice and cul-
tured in the presence of 10 ng/ml IL-3 and vehicle (1:10, 
DMSO/RPMI complete media) or 30 µg/ml MZ. Fresh IL-3 
with either vehicle or MZ was added daily, and mast cell and 
basophil populations were evaluated on day 7 after culture.
Mouse macrophage cultures
BM cells were isolated from the femur of WT mice and cul-
tured in the presence of 30% L cell culture supernatant and 
vehicle (1:10, DMSO/RPMI complete media) or 30 µg/ml 
MZ. Fresh macrophage medium with either vehicle or MZ 
was added daily, and macrophage cell populations were eval-
uated on day 5 after culture.
T. spiralis infection and IL-3C treatment
Methods for maintenance, recovery, infection, and isolation 
of T. spiralis larvae were performed as previously described 
(Urban et al., 2000). Mice were infected with 500 T. spira-
lis muscle larvae by oral gavage and were treated with vehi-
cle (1:5, DMSO/PBS) or 2–3 mg MZ i.p. daily; mice were 
sacrificed between 10 and 11 d after infection. At necropsy, 
single-cell suspensions of mLNs and spleens were prepared 
as previously described (Giacomin et al., 2012) for basophil 
and mast cell analysis. Blood was collected, and serum was 
isolated for analysis of Mcpt1 and IgE. 1-cm sections of small 
intestine (jejunum) were collected for real-time PCR and 
histological analysis. The remaining sections of small intes-
tine were slit lengthwise, rinsed in PBS, and placed in HBSS 
for 4 h at 37°C, and adult worms were quantified by micro-
scopic analysis as previously described (Urban et al., 2000). 
Rag1−/− mice were injected i.p. with a combination of 1 µg 
of recombinant IL-3 and 0.5 µg α–IL-3 antibody (clone 
MP2-8F8; BioLegend) in 200 µl PBS every 3 d for 7–10 d. 
IL-3C–treated mice were treated with 2 mg MZ or vehicle 
(1:5, DMSO/PBS) every day.
RNA isolation and quantitative real-time PCR analysis
RNA from sections of small intestine was isolated by ho-
mogenization in TRIzol (Invitrogen) followed by phe-
nol-chloroform extraction and isopropanol precipitation. 
cDNA was generated per standard protocol with Superscript 
reverse transcription (Invitrogen) and used as an input for re-
al-time PCR. Real-time data were analyzed using the ΔΔ 
cycle threshold (CT) method using SYBR green chemistry 
(Applied Biosystems) with β-actin serving as the endoge-
nous housekeeping gene. All reactions were run on a Fast 
Real-Time PCR system (ABI 7500; Applied Biosystems). 
Samples were normalized to naive controls. The following 
QuantiTech primer assays from QIA GEN were used: Mcpt1 
(QT00157864), IL-4 (QT00160678), IL-9 (QT00107555), 
Arg1 (QT00134288), Retnla (QT00254359), Car1 
(QT01058113), and Car2 (QT00494592).
T cell stimulations and ELI SAs
Single-cell suspensions were made from mLNs or skin drain-
ing LNs. LN cells were cultured in RPMI complete medium 
and treated with and without anti-CD3 (clone 145-2C11; 
BD) and anti-CD28 antibodies (clone 37.51; BD) for 72 h. 
Standard sandwich ELI SA (eBioscience) was performed to 
measure IL-4 (clones 11B11 and BVD6-24G2), IL-5 (clones 
TRFK5 and TRFK4), and IL-13 (clones eBio13A and 
eBio1316H) levels in the cell-free supernatants. Serum quan-
tities of Mcpt1 and IgE were measured by commercial sand-
wich ELI SA kits (BD; eBioscience).
Atopic dermatitis–like disease
Mice were treated once a day topically with 2 nmol of 
MC903 (calcipotriol; Tocris Bioscience) in 20 µl ethanol for 
6 d as described previously (Kim et al., 2013). MC903-treated 
mice were treated with vehicle (1:5, DMSO/PBS) or 2–3 mg 
MZ i.p. daily and sacrificed on day 7 after treatment.
Preparation of A. fumigatus conidia
A. fumigatus strain Af293 was grown on glucose minimal 
media agar plates for 3 d or sabouraud dextrose agar for 7–10 d 
at 37°C. Conidia were harvested by adding 0.01% Tween 80 to 
plates and gently scraping conidia from the plates using a cell 
scraper. Conidia were then filtered through sterile Miracloth, 
washed, resuspended in PBS, and counted on a hemocytom-
eter (3520; Hausser Scientific). Fluorescent A. fumigatus re-
porter conidia were prepared as previously described (Espinosa 
et al., 2014). Mice were challenged with 5 × 107 A. fumigatus 
conidia intratracheally as described previously (Espinosa et al., 
2014). Mice were treated with vehicle (1:5, DMSO/PBS) or 
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2–3 mg MZ i.p. daily and sacrificed 72 h after infection. Bron-
choalveolar lavage fluid was collected by washing the lungs 
with 2 ml PBS containing 0.05 M EDTA. After collection of 
the bronchoalveolar lavage fluid, lung samples were minced 
in RPMI containing 100 units/ml collagenase (Gibco), incu-
bated at 37°C for 60 min, disrupted, and filtered. Subsequently, 
red blood cells were lysed using a Tris ammonium chloride 
solution. Analysis of neutrophils was conducted using a panel 
of cell surface markers (CD45, CD11b, and Ly6G) as previ-
ously described (Espinosa et al., 2014). To deplete lung neu-
trophils, mice were injected with 500 µg anti-Ly6G antibody 
(clone 1A8; Bio X Cell) i.p. followed by another dose of 100 
µg intratracheally (Espinosa et al., 2014).
Food allergy
Food allergy–like disease was initiated as previously described 
(Noti et al., 2014). In brief, mice were treated daily with 2 
nmol MC903 (calcipotriol; Tocris Bioscience) in 20  µl of 
100% ethanol on ears in the presence of 100 µg OVA daily 
for 14 d. As a vehicle control, the same volume of ethanol 
and OVA was applied. All mice were challenged intragastri-
cally with 50 mg OVA on days 14–17.5. Mice were sacrificed 
on day 18. Groups of mice were treated with vehicle (1:5, 
DMSO/PBS) or 2–3 mg MZ i.p. daily until sacrifice.
BM chimeras
Mice were lethally irradiated (1,050 rad) and reconstituted 
with 106 WT BM cells, 106 Car2−/− BM cells, or a mix of 5 × 
105 WT and 5 × 105 Car2−/− BM cells. Mice were allowed to 
reconstitute for a period of 8 wk.
Mouse ESC culture
R1 mouse ESCs (Nagy et al., 1993) were provided by A. 
Gravy (Lunenfeld-Tanenbaum Research Institute, Mount 
Sinai Hospital, Toronto, Ontario, Canada) and cultured as de-
scribed previously (Lin and Talbot, 2011). In brief, irradiated 
MEFs (R&D Systems) were cultured according to the man-
ufacturer’s protocol. 1 d later, 106 ESCs were cultured over 
MEFs for ∼4 d until they reached a confluence of ∼80–90%. 
The medium was replaced every 24 h. ESCs and MEFs were 
detached using StemPro Accutase cell dissociation reagent 
(Thermo Fisher Scientific) following the manufacturer’s in-
structions until cell suspensions were obtained. Cell suspen-
sions were then plated on gelatin-coated vessels for 45 min to 
separate MEFs from ESCs.
CRI SPR/Cas9 transfections
CRI SPR/Cas9 genome editing was performed as described 
previously (Kim et al., 2014b). 1 µg/µl Cas9 nuclease (Invi-
trogen) was incubated with 240 ng/µl in vitro transcribed 
guide RNAs (Invitrogen) targeting the gene encoding 
Car1 (5′-AGA ATA TCT AGT TCC ATC CA-3′) according 
to manufacturer’s instructions. 106 ESCs were washed once 
with 1× PBS and resuspended in 50 µl of resuspension buf-
fer. 5 µl ESC suspension was mixed with 7 µl Cas9/gRNA 
complexes, and cells were electroporated using the Neon 
Transfection System (1300V; 10 width and 3 pulses; Invit-
rogen). Mock-transfected control cells were electroporated 
with Cas9 protein only. ESCs were cultured over MEFs 
immediately after transfection and until they reached a con-
fluence of 80–90%. Genome targeting efficiency was de-
termined as previously described (Guschin et al., 2010). In 
brief, genomic DNA was isolated using the QIAamp DNA 
mini kit (QIA GEN). Then, a 600-bp gene region containing 
the targeted sequence for car1 was amplified by PCR (for-
ward primer: 5′-GCT CTG TGA TTA AAG TCC AG-3′; re-
verse primer: 5′-TTC CAT CGT GCA CAA GGCA-3′). The 
PCR product was reannealed and incubated with 1 µl T7 
endonuclease (New England Biolabs, Inc.). PCR products 
were run on a 2% agarose gel, and the band’s percentage 
intensity was analyzed using the Image Lab software (Bio-
Rad Laboratories). After genome targeting efficiency assays, 
aliquots of cells from this parent culture of ∼3 × 106 cell 
were removed and plated for developmental assays.
Mast cell and macrophage differentiation from ESCs
Mast cell and macrophage differentiation was performed as 
previously described (Kovarova and Koller, 2012). In brief, 
ESCs were cultured with 9  ml of differentiation medium 
(α-MEM supplemented with 15% ESC-qualified FBS, pen-
icillin/streptomycin, 5% of protein-free hybridoma medium, 
insulin transferrin selenium supplement, 1-thioglycerol, and 
ascorbic acid) on Petri dishes for 10 d replacing the medium 
every 3 d to generate embryonic bodies. Embryonic bod-
ies were dissociated as described previously (Kovarova and 
Koller, 2012) and washed. 5 × 105 cells were plated and treated 
with 10 ng/ml recombinant IL-3 to generate mast cells or 
with 30% L cell culture supernatant to induce macrophage 
differentiation. The media was replaced every 48 h. After 3 
wk of culture, mast cell and macrophage populations were 
analyzed by flow cytometry.
Human mast cell cultures
Blood from healthy human donors was obtained from the 
New York Blood Center under protocols approved by the 
Rutgers Institutional Review Boards. Peripheral blood cells 
were isolated using a Ficoll gradient. CD34+ cells were pu-
rified using a CD34 MicroBead isolation kit according to 
the manufacturer’s protocol (130-048-702; Miltenyi Biotec). 
25–50 × 103 CD34+ cells were placed in methocult (H4236) 
supplemented with stem cell factor, IL-6, and IL-3 as de-
scribed previously (Saito et al., 2006). Mast cell populations 
were evaluated on day 14 after culture.
Statistics
Results are shown as mean ± SD. Statistical analy-
sis was performed using Student’s t tests in Prism (ver-
sion 6; GraphPad Software).
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